CVS faces significant 2025 headwinds, including intense pharmacy competition, threatened new federal government pressures, excessive leverage/debt, plus

You can't miss these CVS deals on Monday, January 20. On sale are product from categories like: Beauty, medicine, vitamins, diet and personal care.

CVS Health shares are trading lower by 2.7% during Thursday's session. Shares of insurers and pharmacy benefit manager stocks are trading lower in possible reaction to UnitedHealth's quarterly revenue miss.

We recently published a list of 10 Firms Dominate Monday Upsurge. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against other firms that dominated Monday upsurge.

CVS Health ( CVS 4.35%) is a stock that's been struggling badly for multiple years and is coming off a brutal performance in 2024, when its shares nose-dived by 43%.

This week's dividend activity included increased payouts from Lakeland Financial (LKFN) and Valero Energy (VLO) as well as declarations from companies such as Citigroup (NYSE:C) and Procter & Gamble (NYSE:PG).

CVS Health has disclosed plans to lay off another 13 employees who are based at or report to its offices at 151 Farmington Ave., in Hartford.

Shares of CVS Health Corp. CVS advanced 1.11% to $52.14 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.83% to 5,949.91 and the Dow Jones Industrial Average DJIA rising 1.

CVS Health® (NYSE: CVS) will hold a conference call with analysts and investors on Wednesday, February 12th, 2025, at 8:00 a.m. ET to discuss fourth quarter and full year 2024 financial results.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CVS faces strong competition from Amazon, Walmart, and Costco, impacting market share. Read why I maintain a Hold rating for CVS stock.

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.